Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition ; volume:18 ; number:1 ; day:5 ; month:4 ; year:2016 ; pages:1-13 ; date:12.2016
Breast cancer research ; 18, Heft 1 (5.4.2016), 1-13, 12.2016
- Creator
-
Leroy, Cedric
- Contributor
-
Ramos, Pedro
Cornille, Karen
Bonenfant, Debora
Fritsch, Christine
Voshol, Hans
Bentires-Alj, Mohamed
SpringerLink (Online service)
- DOI
-
10.1186/s13058-016-0697-1
- URN
-
urn:nbn:de:1111-201604069428
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Leroy, Cedric
- Ramos, Pedro
- Cornille, Karen
- Bonenfant, Debora
- Fritsch, Christine
- Voshol, Hans
- Bentires-Alj, Mohamed
- SpringerLink (Online service)
Other Objects (12)
Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
PI3K-Inhibition im Pankreaskarzinommodell
A novel phosphatidylinositol-3-kinase (PI3K)-IL-22 axis confers resistance to T-cell mediated autoimmunity
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts
FADS2 confers SCD1 inhibition resistance to cancer cells by modulating the ER stress response
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation
Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
PI3K-Inhibition im Pankreaskarzinommodell
A novel phosphatidylinositol-3-kinase (PI3K)-IL-22 axis confers resistance to T-cell mediated autoimmunity
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts
FADS2 confers SCD1 inhibition resistance to cancer cells by modulating the ER stress response
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation
Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
PI3K-Inhibition im Pankreaskarzinommodell
A novel phosphatidylinositol-3-kinase (PI3K)-IL-22 axis confers resistance to T-cell mediated autoimmunity
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts
FADS2 confers SCD1 inhibition resistance to cancer cells by modulating the ER stress response
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance